The U.S. Food and Drug Administration (FDA) has approved sparsentan as the first-ever treatment for focal segmental glomerulosclerosis (FSGS), a rare and often progressive kidney disease. The drug, developed by Travere Therapeutics, received accelerated approval based on promising clinical trial results showing reduced proteinuria in patients.
FSGS affects approximately 40,000 Americans and can lead to kidney failure, with limited treatment options available until now. Sparsentan, a dual endothelin and angiotensin receptor antagonist, demonstrated a 50% reduction in proteinuria compared to standard therapy in Phase 3 trials, according to regulatory filings.
“This approval marks a significant milestone for patients who have faced this devastating disease with few therapeutic choices,” said a spokesperson for the National Kidney Foundation. Analysts note the drug could generate $300 million in annual sales by 2028, though some experts caution about potential liver toxicity risks that require monitoring.
The approval comes with a Risk Evaluation and Mitigation Strategy (REMS) program due to potential hepatotoxicity concerns. Industry observers suggest this decision may pave the way for faster approvals of other rare disease treatments, particularly those addressing unmet needs in nephrology.